Available Technology

Novel Analogues of the Asthma Drug Fenoterol as Liver and Brain Cancer Therapeutic Agents

Available for licensing are specific fenoterol analogues, such as MNF, that inhibit the growth of various types of cancers, including brain, liver, colon, and lung tumors. MNF acts as an agonist of the GPRSS cannabinoid (CB) receptor and, as such, represents one of the first potential drugs directed at this target. MNF crosses the blood brain barrier and initial toxicity studies indicate that it has few off-target effects. These new analogues can be used to treat CB receptor related disorders and diseases, and in particular GRPSS-related disorders and diseases, including brain and liver cancers for which there are no current effective treatments.
Abstract: 
Available for licensing are specific fenoterol analogues, such as MNF, that inhibit the growth of various types of cancers, including brain, liver, colon, and lung tumors. MNF acts as an agonist of the GPRSS cannabinoid (CB) receptor and, as such, represents one of the first potential drugs directed at this target. MNF crosses the blood brain barrier and initial toxicity studies indicate that it has few off-target effects. These new analogues can be used to treat CB receptor related disorders and diseases, and in particular GRPSS-related disorders and diseases, including brain and liver cancers for which there are no current effective treatments.
Benefits: 
Able to cross the blood:brain barrier. -Few side-effects. -Broad range of therapeutic activity. -Can be formulated for oral administration.
applications: 
Inventors: 
Irving Wainer
Patent Number: 
61/651,961
Internal Laboratory Ref #: 
E-139-2012/0
Lab Representatives
Share to Facebook Share to Twitter Share to Google Plus Share to Linkedin